Martin F. Fromm
Martin F. Fromm
Chair, Professor of Clinical Pharmacology and Clinical Toxicology, Friedrich-Alexander-University
Bestätigte E-Mail-Adresse bei - Startseite
Zitiert von
Zitiert von
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
RB Kim, MF Fromm, C Wandel, B Leake, AJ Wood, DM Roden, ...
The Journal of clinical investigation 101 (2), 289-294, 1998
Pharmacokinetic interactions with rifampicin: clinical relevance
M Niemi, JT Backman, MF Fromm, PJ Neuvonen, KT Kivistö
Clinical pharmacokinetics 42, 819-850, 2003
OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine
M Cvetkovic, B Leake, MF Fromm, GR Wilkinson, RB Kim
Drug metabolism and disposition 27 (8), 866-871, 1999
Cytochrome P450 2C19 681G> A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary …
D Trenk, W Hochholzer, MF Fromm, LE Chialda, A Pahl, CM Valina, ...
Journal of the American College of Cardiology 51 (20), 1925-1934, 2008
Importance of P-glycoprotein at blood–tissue barriers
MF Fromm
Trends in pharmacological sciences 25 (8), 423-429, 2004
Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4
RK Bhardwaj, H Glaeser, L Becquemont, U Klotz, SK Gupta, MF Fromm
Journal of Pharmacology and Experimental Therapeutics 302 (2), 645-650, 2002
Transporters and drug-drug interactions: important determinants of drug disposition and effects
J König, F Müller, MF Fromm
Pharmacological reviews 65 (3), 944-966, 2013
Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein
RB Kirn, C Wandel, B Leake, M Cvetkovic, MF Fromm, PJ Dempsey, ...
Pharmaceutical research 16, 408-414, 1999
Inhibition of P-glycoprotein–mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine
MF Fromm, RB Kim, CM Stein, GR Wilkinson, DM Roden
Circulation 99 (4), 552-557, 1999
P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.
MF Fromm
International journal of clinical pharmacology and therapeutics 38 (2), 69-74, 2000
The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells
M Hitzl, S Drescher, H van der Kuip, E Schäffeler, J Fischer, M Schwab, ...
Pharmacogenetics and Genomics 11 (4), 293-298, 2001
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
M Niemi, E Schaeffeler, T Lang, MF Fromm, M Neuvonen, C Kyrklund, ...
Pharmacogenetics and Genomics 14 (7), 429-440, 2004
ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin
JE Keskitalo, O Zolk, MF Fromm, KJ Kurkinen, PJ Neuvonen, M Niemi
Clinical Pharmacology & Therapeutics 86 (2), 197-203, 2009
Genetic Polymorphisms of the Human MDR1 Drug Transporter
M Schwab, M Eichelbaum, MF Fromm
Annual review of pharmacology and toxicology 43 (1), 285-307, 2003
Pharmacogenomics of human OATP transporters
J König, A Seithel, U Gradhand, MF Fromm
Naunyn-Schmiedeberg's archives of pharmacology 372, 432-443, 2006
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis
M Schwab, E Schaeffeler, C Marx, MF Fromm, B Kaskas, J Metzler, ...
Gastroenterology 124 (1), 26-33, 2003
Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene
A Johne, K Köpke, T Gerloff, I Mai, S Rietbrock, C Meisel, S Hoffmeyer, ...
Clinical Pharmacology & Therapeutics 72 (5), 584-594, 2002
Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with …
W Hochholzer, D Trenk, MF Fromm, CM Valina, C Stratz, HP Bestehorn, ...
Journal of the American College of Cardiology 55 (22), 2427-2434, 2010
Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin
MF Fromm, D Busse, HK Kroemer, M Eichelbaum
Hepatology 24 (4), 796-801, 1996
The effect of rifampin treatment on intestinal expression of human MRP transporters
MF Fromm, HM Kauffmann, P Fritz, O Burk, HK Kroemer, RW Warzok, ...
The American journal of pathology 157 (5), 1575-1580, 2000
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20